Tarsus Pharmaceuticals (Tarsus Pharmaceuticals) Cash-to-Debt : 9.78 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Tarsus Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Tarsus Pharmaceuticals's cash to debt ratio for the quarter that ended in Mar. 2024 was 9.78.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Tarsus Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Tarsus Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

TARS' s Cash-to-Debt Range Over the Past 10 Years
Min: 7.12 Med: 37.16 Max: No Debt
Current: 9.78

During the past 6 years, Tarsus Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 7.12. And the median was 37.16.

TARS's Cash-to-Debt is ranked better than
55.77% of 1535 companies
in the Biotechnology industry
Industry Median: 6.49 vs TARS: 9.78

Tarsus Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Tarsus Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Tarsus Pharmaceuticals Cash-to-Debt Chart

Tarsus Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

353.37

202.32

90.86

10.77

7.53

Tarsus Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															7.98	7.12	8.19	7.53	9.78

Competitive Comparison of Tarsus Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Tarsus Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tarsus Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Tarsus Pharmaceuticals's Cash-to-Debt falls into.

Tarsus Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Tarsus Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	227.442	/	(0.398	+	29.819)
	=	7.53

Tarsus Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	298.524	/	(0.585	+	29.933)
	=	9.78

Tarsus Pharmaceuticals (NAS:TARS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Tarsus Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Tarsus Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Tarsus Pharmaceuticals (Tarsus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tarsus Pharmaceuticals Inc (NAS:TARS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

15440 Laguna Canyon Road, Suite 160, Irvine, CA, USA, 92618

Website

https://www.tarsusrx.com

Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03 is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

Executives

Bobak R. Azamian	director, 10 percent owner, officer: President and CEO	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Jose M. Trevejo	officer: Chief Medical Officer	C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Andrew D. Goldberg	director	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Dianne C. Whitfield	officer: Chief Human Resources Officer	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Bryan Wahl	officer: General Counsel	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Elizabeth Yeu Lin	director	25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
Aziz Mottiwala	officer: Chief Commercial Officer	233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Jeffrey S Farrow	officer: See Remarks	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Leonard M. Greenstein	officer: Chief Financial Officer	24562 BELGREEN PLACE, LAKE FOREST CA 92630
Seshadri Neervannan	officer: Chief Operating Officer	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Mark J. Holdbrook	officer: V.P., Clinical Affairs	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Scott W Morrison	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Vivo Capital Fund Ix, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Michael Ackermann	director, 10 percent owner	202 CARNEGIE CENTER, SUITE 109, PRINCETON NJ 08540
Rosemary A Crane	director	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873